Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Johnson & JohnsonNYSE: JNJ
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $8.53B (cash outflow) fell 4.4% year over year, behind the +229.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.
Context
- Financing cash flow amounted to 5.9% of revenue in FY2025, up 2.4 pp from a year earlier.
- Financing cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.4% toward the trailing-twelve-month pace of +229.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (5.54B) USD
- Year-over-year change
- -76.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | (5.54B) | -76.9% |
| FY2024 | 2024-12-29 | (3.13B) | +80.2% |
| FY2023 | 2023-12-31 | (15.83B) | -78.4% |
| FY2022 | 2023-01-01 | (8.87B) | +36.8% |
| FY2021 | 2022-01-02 | (14.05B) | — |
Financing Cash Flow vs competitors
How JNJ compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +229.4% is the 2nd highest of 11, against a peer median of +11.1%.
- Financing cash flow amounts to 18.3% of revenue for JNJ, versus a peer median of 12.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $18.15B USD | +229.4% | -14.5% | 18.3% | |
| LTM Jun 2026 | $12.89B USD | -7.3% | -19.9% | 20.0% | |
| LTM Jun 2026 | $11.71B USD | +40.7% | -15.2% | 23.8% | |
| LTM Jun 2026 | €9.13B EUR | +1442.5% | +16.7% | 18.7% | |
| LTM Jun 2026 | $8.4B USD | -53.8% | -11.4% | 13.2% | |
| LTM Jun 2026 | $6.17B USD | +141.8% | -40.5% | 9.3% | |
| LTM Sep 2026 | $5.39B USD | +9.1% | +3.4% | 8.7% | |
| LTM Jun 2026 | $4.65B USD | +13.0% | +6.2% | 15.3% | |
| LTM Jun 2026 | $4.13B USD | -65.2% | +39.1% | 10.8% | |
| LTM Jun 2026 | £2.53B GBP | -29.6% | — | 7.6% | |
| LTM Jun 2026 | $472.2M USD | +102.8% | -10.1% | 0.8% | |
| Peer median (excluding JNJ) | — | +11.1% | -10.1% | 12.0% | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.88B | 17.94B | 13.33B | 14.07B | 26.8B |
| Depreciation & Amortization | 7.39B | 6.97B | 7.49B | 7.34B | 7.5B |
| Deferred Income Tax | (2.08B) | (1.66B) | (4.19B) | (2.18B) | 1.54B |
| Stock-Based Compensation | 1.14B | 1.14B | 1.16B | 1.18B | 1.35B |
| Change in Working Capital | (4.24B) | (4.01B) | 2.51B | 1.84B | (12.72B) |
| Accounts Receivables | (2.4B) | (1.29B) | (624M) | (406M) | (1.78B) |
| Inventory | (1.25B) | (2.53B) | (1.32B) | (1.13B) | (1.45B) |
| Accounts Payables | 2.44B | 1.1B | 2.35B | 1.62B | 2.38B |
| Other Working Capital | (3.03B) | (1.29B) | 2.11B | 1.75B | (11.86B) |
| Other Non-Cash Items | 324M | 819M | 2.5B | 2.03B | 49M |
| Operating Cash Flow | 23.41B | 21.19B | 22.79B | 24.27B | 24.53B |
| Capital Expenditures | (3.65B) | (4.01B) | (4.54B) | (4.42B) | (4.83B) |
| Acquisitions (Net) | (60M) | (17.65B) | 358M | (15.15B) | (17.54B) |
| Purchases of Investments | (30.39B) | (32.38B) | (10.91B) | (1.73B) | (920M) |
| Sales of Investments | 25.01B | 41.61B | 19.39B | 2.46B | 1.66B |
| Other Investing Activities | 417M | 65M | (3.42B) | 235M | (1.96B) |
| Investing Cash Flow | (8.68B) | (12.37B) | 878M | (18.6B) | (23.59B) |
| Debt Repayment | (990M) | 7.45B | (2.73B) | 10.05B | 9.64B |
| Common Stock Issued | 0 | 0 | 4.24B | 0 | 0 |
| Common Stock Repurchased | (3.46B) | (6.04B) | (5.05B) | (2.43B) | (5.95B) |
| Dividends Paid | (11.03B) | (11.68B) | (11.77B) | (11.82B) | (12.38B) |
| Other Financing Activities | 1.43B | 1.39B | (508M) | 1.07B | 3.16B |
| Financing Cash Flow | (14.05B) | (8.87B) | (15.83B) | (3.13B) | (5.54B) |
| Effect of Forex Changes | (178M) | (312M) | (112M) | (289M) | 201M |
| Net Change in Cash | 502M | (360M) | 7.73B | 2.25B | (4.4B) |
| Free Cash Flow | 19.76B | 17.19B | 18.25B | 19.84B | 19.7B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.